Gene Expression Profiling Provides Insight on SMZL Cell of Origin and its Relationship to CLL
Advisor Information
Dr. Christine Cutucache
Location
Room 225
Presentation Type
Oral Presentation
Start Date
1-3-2019 2:15 PM
End Date
1-3-2019 3:15 PM
Abstract
Splenic marginal zone lymphoma (SMZL) is lagging behind and in the pioneer-age of accurate diagnostic methods for the disease, partly due to its heterogeneity. There exists a present need to be where chronic lymphocytic leukemia (CLL) is at in relation to diagnostic accuracy for SMZL, particularly as it pertains to cases that will lead to worse clinical outcomes and disease progression. Chronic lymphocytic leukemia and splenic marginal zone lymphoma parallel each other in a number of descriptors, including the following: heterogeneity, worse patient outcomes in a subset of both diseases, and in pathways that are affected. We aimed to test whether B cell subset characterization would provide a unique subpopulation between the two diseases to aid in SMZL treatment options. In using gene expression profiling data, we aimed in further determining the cell of origin for the disease, in addition to exploring whether CLL can be thought of as a parallel disease with a common cell of origin. Data aims in helping characterize the disease, in addition to proposing a parallel nature to CLL to aid in unique niches that could be potential treatment targets moving forward.
Gene Expression Profiling Provides Insight on SMZL Cell of Origin and its Relationship to CLL
Room 225
Splenic marginal zone lymphoma (SMZL) is lagging behind and in the pioneer-age of accurate diagnostic methods for the disease, partly due to its heterogeneity. There exists a present need to be where chronic lymphocytic leukemia (CLL) is at in relation to diagnostic accuracy for SMZL, particularly as it pertains to cases that will lead to worse clinical outcomes and disease progression. Chronic lymphocytic leukemia and splenic marginal zone lymphoma parallel each other in a number of descriptors, including the following: heterogeneity, worse patient outcomes in a subset of both diseases, and in pathways that are affected. We aimed to test whether B cell subset characterization would provide a unique subpopulation between the two diseases to aid in SMZL treatment options. In using gene expression profiling data, we aimed in further determining the cell of origin for the disease, in addition to exploring whether CLL can be thought of as a parallel disease with a common cell of origin. Data aims in helping characterize the disease, in addition to proposing a parallel nature to CLL to aid in unique niches that could be potential treatment targets moving forward.
Additional Information (Optional)
I will bring the presentation on a flash drive on Friday, March 1st.